GH Research PLC reported positive Phase IIb data on 3 February for GH-001 (mebufotenin), an inhalation formulation of the psychedelic compound synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in treatment-resistant depression (TRD), a readout that one analyst said “reinforces GH-001’s blockbuster potential.”
GH’s Phase IIb Data Show Potential Differentiation In Depression
Seeking to bring its psychedelic candidate to market in treatment-resistant depression, Ireland’s GH sees its drug-device inhalation combo product as offering strong differentiation versus Spravato.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus